Hepatitis Forums

Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on July 02, 2019, 10:29:59 am

Title: Disappointing Midway Trial Results for Emricasan as Treatment for NASH
Post by: Hep Editors on July 02, 2019, 10:29:59 am

Halfway through a 48-week trial, Conatus Pharmaceuticals’ emricasan showed a trend toward a lack of efficacy as treatment for non-alcoholic steatohepatitis (NASH), MedPage Today reports. While the trial must complete before a proper assessment of the drug’s efficacy can be assessed, the 24-week results are not promising.

Presenting their findings at the 53rd International Liver Congress in Vienna, researchers conducted a multicenter randomized trial at 59 sites in the United States and the European Union. The study enrolled 263 people with NASH cirrhosis and an initial hepatic venous pressure gradient (HVPG) of at least 12 millimeters of mercury (mmHg).

Read more...
https://www.hepmag.com/article/disappointing-midway-trial-results-emricasan-treatment-nash